Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Taniguchi (Kobe, Japan), Y. Matsuoka (Kobe, Japan), H. Onishi (Kobe, Japan), N. Emoto (Kobe, Japan), H. Nakai (Kobe, Japan), K. Okada (Kobe, Japan), K. Hirata (Kobe, Japan). Survival in patients with chronic thromboembolic pulmonary hypertension in the modern management era. 1542

Member's Comments

No comment yet.

Related content which might interest you: Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era Source: Eur Respir J, 51 (6) 1800307; 10.1183/13993003.00307-2018 Year: 2018 Genetic diagnostics in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019 Survival in medically treated chronic thromboembolic pulmonary hypertension patients Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 A roadmap for management of chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 54 (4) 1901295; 10.1183/13993003.01295-2019 Year: 2019 Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 272-282 Year: 2015 Current management of patients with chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Improved survival in medically-treated chronic thromboembolic pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients Source: Eur Respir J, 52 (5) 1800248; 10.1183/13993003.00248-2018 Year: 2018 The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 52 (3) 1800589; 10.1183/13993003.00589-2018 Year: 2018 Chronic thromboembolic pulmonary hypertension Source: Eur Respir Mon 2012; 57: 108-118 Year: 2012 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Pulmonary angioplasty vs exclusive medical treatment in inoperable chronic thromboembolic hypertension–initial outcomes from a pulmonary hypertension centre Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Chronic thromboembolic pulmonary hypertension: advances from bench to patient management Source: Eur Respir J 2013; 41: 8-9 Year: 2013 The changing landscape of chronic thromboembolic pulmonary hypertension management Source: Eur Respir Rev, 26 (146) 170105; 10.1183/16000617.0105-2017 Year: 2017